A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GSK2578999A | GSK2578999A is a potent HIV-1 maturation inhibitor with IC50 values of 17 nM, 23 nM, 25 nM, and 8 nM for wild type, Q369H, V370A, and T371A respectively. Synonyms: GSK-8999; (3β)-3-(3-carboxy-3-methyl-1-oxobutoxy)-N-[1-(4-chlorophenyl)cyclopropyl]-α,21-dioxo-28-norlup-18-ene-17-acetamide. CAS No. 1422355-59-6. Molecular formula: C46H62ClNO7. Mole weight: 776.4. |  |
| GSK2593074A | GSK2593074A is a necroptosis inhibitor for dual-targeting to both RIP1 and RIP3. Synonyms: GSK'074; 7-(1-methyl-1H-pyrazol-4-yl)-3-[1-(phenylacetyl)-2,3-dihydro-1H-indol-5-yl]thieno[3,2-c]pyridin-4-amine. Grade: 99%. CAS No. 1337531-06-2. Molecular formula: C27H23N5OS. Mole weight: 465.57. | |
| GSK2606414 | GSK2606414 is a cell-permeable and orally available protein kinase R-like endoplasmic reticulum (ER) kinase (PERK) inhibitor with an IC50 of 0.4 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1337531-36-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18072. |  |
| GSK 2606414 | GSK 2606414 is a potent and selective PERK inhibitor that suppresses PERK activation in cells and inhibits the growth of a human tumor xenograft in mice. Protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small-molecule inhibitors. Synonyms: GSK2606414; GSK-2606414; GSK 2606414; GSK PERK Inhibitor. 1-(5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-indolin-1-yl)-2-(3-(trifluoromethyl)phenyl)ethanone. Grade: 98%. CAS No. 1337531-36-8. Molecular formula: C24H20F3N5O. Mole weight: 451.453. | |
| GSK 2606414 | GSK 2606414. Group: Biochemicals. Alternative Names: 7-Methyl-5-[1-[[3- (trifluoromethyl) phenyl]acetyl]-2, 3-dihydro-1H-indol-5-yl]-7H-pyrrolo[2, 3-d]pyrimidin-4-amine. Grades: Highly Purified. CAS No. 1337531-36-8. Pack Sizes: 1mg. Molecular Formula: C24H22F3N5O, Molecular Weight: 453.46. US Biological Life Sciences. |  Worldwide |
| GSK2636771 | GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3Kβ with a K i of 0.89 nM and an IC 50 of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms. Uses: Scientific research. Group: Signaling pathways. CAS No. 1372540-25-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15245. | |
| GSK2636771 | GSK2636771 is an orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells. Uses: Antineoplastic agents. Synonyms: GSK2636771; GSK-2636771; GSK 2636771. CAS No. 1372540-25-4. Molecular formula: C22H22F3N3O3. Mole weight: 433.431. | |
| GSK 2636771 dihydrochloride | GSK 2636771 is an orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK 2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells. Synonyms: GSK-2636771 dihydrochloride; GSK2636771 dihydrochloride; 2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid dihydrochloride. Grade: 99%. CAS No. 2108806-07-9. Molecular formula: C22H22F3N3O3.2HCl. Mole weight: 506.35. | |
| GSK 264220A | GSK 264220A is an endothelial lipase and lipoprotein lipase inhibitor (IC50 = 0.13 and 0.10 μM, respectively). Inhibition of endothelial lipase may lead to an increase in HDL levels and GSK 264220A is expected to be a therapy for cardiovascular disease. Uses: Potential treatment of cardiovascular disease. Synonyms: GSK-264220A; GSK 264220A; GSK264220A. N-[2-Methyl-5-(1-piperidinylsulfonyl)-3-furanyl]-N'-phenylurea; 3-[2-methyl-5-(piperidine-1-sulfonyl)furan-3-yl]-1-phenylurea; 1-(2-methyl-5-piperidin-1-ylsulfonylfuran-3-yl)-3-phenylurea. Grade: ≥98% by HPLC. CAS No. 685506-42-7. Molecular formula: C17H21N3O4S. Mole weight: 363.43. | |
| GSK 264220A | GSK 264220A. Group: Biochemicals. Grades: Purified. CAS No. 685506-42-7. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK2643943A | GSK2643943A is a deubiquitinating enzyme (DUB) inhibitor targeting USP20. GSK2643943A has affinity with an IC50 of 160 nM for USP20/Ub-Rho. GSK2643943A has anti-tumor efficacy and can be used for the research of oral squamous cell carcinoma (OSCC) [1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2449301-27-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111458. | |
| GSK2643943A | GSK2643943A is a deubiquitylating enzyme (DUB) inhibitor with IC50 of 160 nM for USP20/Ub-Rho. Synonyms: GSK 2643943A; GSK-2643943A. CAS No. 2449301-27-1. Molecular formula: C17H12FN3. Mole weight: 277.30. | |
| GSK2656157 | GSK2656157 is an ATP-competitive inhibitor of PERK enzyme activity with an IC50 of 0.9 nM. It is highly selective for PERK with IC50 values >100 nM against a panel of 300 kinases. GSK2656157 inhibits PERK activity in cells with an IC50 in the range of 10-30 nM as shown by inhibition of stress-induced PERK autophosphorylation, eIF2α substrate phosphorylation, together with corresponding decreases in ATF4 and CHOP proteins in multiple cell lines. Oral administration of GSK2656157 to mice shows a dose- and time-dependent pharmacodynamic response in pancreas as measured by PERK auto-phosphorylation. Twice daily dosing of GSK2656157 results in dose dependent inhibition of multiple human tumor xenografts growth in mice. Altered amino acid metabolism, decreased blood vessel density and vascular perfusion are potential mechanisms for the observed anti-tumor effect. However, despite its anti-tumor activity, given the on-target pharmacological effects of PERK inhibition on pancreatic function, development of any PERK inhibitor in human subjects would need to be cautiously pursued in cancer patients. Synonyms: GSK2656157; GSK 2656157; GSK-2656157. Grade: 0.98. CAS No. 1337532-29-2. Molecular formula: C23H21FN6O. Mole weight: 416.46. | |
| GSK2656157 | GSK2656157 is a selective and ATP-competitive inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) with an IC50 of 0.9 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1337532-29-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13820. | |
| GSK 269962 | GSK 269962 is a potent ROCK inhibitor with IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively, which displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. It may be used in OAB treatment. It has been shown to block the generation of inflammatory cytokines in lipopolysaccharide-stimulated monocytes and to induce vasorelaxation in preconstricted rat aorta (IC50 = 35 nM). It lowers blood pressure in a rat model of hypertension. It induced a reduction in blood pressure of approximately 10, 20, and 50 mm Hg at doses of 1, 3, and 30 mg/kg. It represent a novel class of ROCK inhibitors that have profound effects in the vasculature, which may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases. Uses: Gsk 269962 may be used in oab treatment. it represent a novel class of rock inhibitors. Synonyms: GSK269962A; N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(4-morpholinyl)ethyl]oxy]benzamide; Aminofurazanyl-azabenzimidazole 6n; N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-6-yl]oxyphenyl]-4-(2-morpholin-4-ylethoxy)benzamide. Grade: >99 %. CAS No. 850664-21-0. Molecular formula: C29H30N8O5. Mole weight: 570.60. | |
| GSK269962A | GSK269962A (GSK 269962) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A has anti-inflammatory and vasodilatory activities[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GSK 269962. CAS No. 850664-21-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-15556. | |
| GSK269962A HCl | GSK269962 is a selective inhibitor of ROCK (Rho-associated protein kinase) with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively. GSK269962 displays > 30-fold selectivity for ROCK against a panel of serine/threonine kinases. Synonyms: GSK269962B; GSK269962; GSK 269962. Molecular formula: C29H30N8O5·HCl. Mole weight: 607.06. | |
| GSK269962A hydrochloride | GSK269962A hydrochloride is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities. Synonyms: GSK269962 HCl; GSK 269962 hydrochloride. CAS No. 2095432-71-4. Molecular formula: C29H31ClN8O5. Mole weight: 607.06. | |
| GSK-269984A | GSK-269984A is a Prostaglandin E2 Receptor 1 antagonist with a pIC50 of 8.1. Synonyms: 2-Pyridinecarboxylic acid, 6-((5-chloro-2-((4-chloro-2-fluorophenyl)methoxy)phenyl)methyl)-, sodium salt. Grade: 95%. CAS No. 892664-04-9. Molecular formula: C20H13Cl2FNNaO3. Mole weight: 428.22. | |
| GSK-270822A | GSK-270822A is a G protein-coupled receptor kinases(GRK2) inhibitor, which has been directly implicated in the progression of heart failure. It would be used as useful chemical probes and leads for therapeutic applications ranging from heart failure to Parkinson's disease. Uses: Gsk-270822a would be used as useful chemical probes and leads for therapeutic applications ranging from heart failure to parkinson's disease. Synonyms: GSK270822A; GSK 270822A; N-(1H-indazol-5-yl)-2-methyl-4-(naphthalen-2-yl)-6-oxo-1,4,5,6-tetrahydropyridine-3-carboxamide; NSC-756163. Grade: 98%. CAS No. 864082-23-5. Molecular formula: C24H20N4O2. Mole weight: 396.45. | |
| GSK2795039 | GSK2795039 is a NADPH oxidase 2 (NOX2) inhibitor with a mean pIC50 of 6 in different cell-free assays. GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption[1].GSK2795039 reduces apoptosis[2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1415925-18-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 100 mg. Product ID: HY-18950. | |
| GSK2795039 | GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) with pIC50 of 6. GSK2795039 inhibited both the formation of ROS and the utilization of the enzyme substrates, NADPH and oxygen, in a variety of semirecombinant cell-free and cell-based NOX2 assays. Synonyms: GSK-2795039; GSK 2795039. CAS No. 1415925-18-6. Molecular formula: C23H26N6O2S. Mole weight: 450.56. | |
| GSK2798745 | GSK2798745 is a potent, selective, and orally active transient receptor potential vanilloid 4 (TRPV4) ion channel blocker with IC50s of 1.8 and 1.6 nM for hTRPV4 and rTRPV4, respectively. GSK2798745 can be used in cardiac and respiratory diseases research[1][2][3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1419609-94-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-19765. | |
| GSK2801 | GSK2801 is a A Selective Chemical Probe for BAZ2B/A bromodomains. BAZ2A/B belong to a family of ubiquitously expressed bromodomain containing proteins.probes/GSK2801). Synonyms: GSK2801; GSK-2801; GSK 2801. Grade: 98%. CAS No. 1619994-68-1. Molecular formula: C20H21NO4S. Mole weight: 371.45. | |
| GSK2801 | GSK2801 is a potent, selective, orally active and cell active acetyl-lysine competitive BAZ2A and BAZ2B bromodomains inhibitor with Kd values of 136 nM and 257 nM, respectively. GSK2801 shows >50-fold selectivity for BAZ2A/B over BRD4[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1619994-68-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-15658. | |
| GSK2801 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. |  |
| GSK2807 Trifluoroacetate | GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive SMYD3 inhibitor, with a Ki of 14 nM and an IC50 of 130 nM. Synonyms: (S)-2-Amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(3-(dimethylamino)propyl)amino)butanoic acid 2,2,2-trifluoroacetic acid; 5'-{[(3S)-3-Amino-3-carboxypropyl][3-(dimethylamino)propyl]amino}-5'-deoxyadenosine trifluoroacetate (1:1); Acetic acid, 2,2,2-trifluoro-, compd. with adenosine, 5'-[[(3S)-3-amino-3-carboxypropyl][3-(dimethylamino)propyl]amino]-5'-deoxy- (1:1). Grade: ≥95%. CAS No. 2245255-66-5. Molecular formula: C21H33F3N8O7. Mole weight: 566.53. | |
| GSK2807 Trifluoroacetate | GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of SMYD3 , with a K i of 14 nM and an IC 50 of 130 nM [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2245255-66-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-104009A. | |
| GSK-2818713 | GSK-2818713 is a second-generation inhibitor of hepatitis C virus (HCV) NS5A replication. Compared to daclatasvir, a first-generation NS5A replication complex inhibitor, GSK-2818713 exhibited picomolar potency on genotype 1 variants. Uses: The treatment of hepatitis c. Synonyms: GSK-2818713; GSK2818713; GSK 2818713. | |
| GSK2830371 | GSK2830371 is an orally active, allosteric Wip1 phosphatase inhibitor with IC50 of 6 nM. Synonyms: GSK 2830371; GSK2830371; GSK-2830371. Grade: >98%. CAS No. 1404456-53-6. Molecular formula: C23H29ClN4O2S. Mole weight: 461.02. | |
| GSK2830371 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK 2830371 | GSK 2830371 is a highly selective Wip1 phosphatase inhibitor with IC50 of 6 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1404456-53-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-15832. | |
| GSK2837808A | GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 1445879-21-9. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100681. | |
| GSK2837808A | GSK2837808A is a potent and specific lactate dehydrogenase A (LDHA) with IC50 values of 1.9 and 14 nM for LDHA and LDHB, respectively and inhibits lactate production in selected cancer cell lines. Synonyms: GSK2837808A; GSK-2837808A; GSK 2837808A; GSK2837808; GSK-2837808; GSK 2837808. 3-[[3-(cyclopropylsulfamoyl)-7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4-yl]amino]-5-(3,5-difluorophenoxy)benzoic acid. CAS No. 1445879-21-9. Molecular formula: C31H25F2N5O7S. Mole weight: 649.62. | |
| GSK2838232 | GSK2838232, a derivative of Betulin, is a novel human immune virus (HIV) maturation inhibitor being developed for the treatment of chronic HIV infection. Uses: Anti-hiv agents. Synonyms: GSK2838232; GSK-2838232; GSK 2838232; 4-[[(3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-[(1R)-2-[(4-chlorophenyl)methyl-[2-(dimethylamino)ethyl]amino]-1-hydroxyethyl]-5a,5b,8,8,11a-pentamethyl-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3H-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dime. Grade: 99.34%. CAS No. 1443460-91-0. Molecular formula: C48H73ClN2O6. Mole weight: 809.56. | |
| GSK2850163 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK2850163 hydrochloride | GSK2850163 hydrochloride, an inositol-requiring enzyme-1 alpha (IRE1α) inhibitor, can inhibit IRE1α kinase activity and RNase activity with IC50s of 20 and 200 nM, respectively. Synonyms: 2,7-Diazaspiro[4.5]decane-7-carboxamide, 2-[(3,4-dichlorophenyl)methyl]-N-[(4-methylphenyl)methyl]-, hydrochloride (1:1), (5R)-; (5R)-2-(3,4-Dichlorobenzyl)-N-(4-methylbenzyl)-2,7-diazaspiro[4.5]decane-7-carboxamide hydrochloride (1:1). CAS No. 2319838-09-8. Molecular formula: C24H30Cl3N3O. Mole weight: 482.87. | |
| GSK2879552 | GSK2879552 an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/ KDM1A), with potential antineoplastic activity[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1401966-69-5. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18632. | |
| GSK2879552 | GSK2879552 has been found to be a LSD1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells. It was just planed a Phase I/II trail by GSK against Myelodysplastic syndromes. Uses: Gsk2879552 has been found to be a lsd1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells. Synonyms: GSK2879552; UNII-GT77Z6Y09Z; GSK-2879552; GSK 2879552; GT77Z6Y09Z; 1401966-69-5; 4-((4-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid. Grade: 98%. CAS No. 1401966-69-5. Molecular formula: C23H28N2O2. Mole weight: 364.48. | |
| GSK2879552 | GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, GSK2879552 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the dimethylated form of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK2879552; GSK-2879552; GSK 2879552. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1401966-69-5. Molecular formula: C23H28N2O2. Mole weight: 364.48. Purity: >98%. IUPACName: 4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid. Canonical SMILES: O=C(O)C1=CC=C(CN2CCC(CN[C@H]3[C@H](C4=CC=CC=C4)C3)CC2)C=C1. Product ID: ACM1401966695. Alfa Chemistry ISO 9001:2015 Certified. |  |
| GSK2879552 dihydrochloride | GSK2879552 dihydrochloride, a selective, irreversible and orally active lysine specific demethylase 1 (LSD1/KDM1A) inhibitor, has potential antineoplastic activity. Synonyms: Benzoic acid, 4-[[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]-1-piperidinyl]methyl]-, hydrochloride (1:2); 4-{[4-({[(1R,2S)-2-Phenylcyclopropyl]amino}methyl)-1-piperidinyl]methyl}benzoic acid dihydrochloride. Grade: ≥95%. CAS No. 1902123-72-1. Molecular formula: C23H30Cl2N2O2. Mole weight: 437.40. | |
| GSK2879552 dihydrochloride | GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1902123-72-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18632A. | |
| GSK-2881078 | GSK-2881078, an indole derivative, has been found to be an androgen receptor modulator that could probably be effective against Cachexia. It is still under Phase I trail. Uses: Anabolic agents. Synonyms: GSK 2881078; GSK2881078; CS-5736; (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile. Grade: 98%. CAS No. 1539314-06-1. Molecular formula: C14H13F3N2O2S. Mole weight: 330.33. | |
| GSK-2894631A | GSK2894631A is an inhibitor of hematopoietic PGD synthase (HPGDS). Synonyms: HPGDS inhibitor 2. CAS No. 2101626-26-8. Molecular formula: C20H24F2N2O3. Mole weight: 378.4. | |
| GSK2982772 | GSK2982772, with potential effect to treat inflammatory diseases, potently binds to RIP1 with exquisite kinase specificity. In phase 2a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis. Synonyms: GSK2982772; GSK 2982772; GSK-2982772; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide. CAS No. 1622848-92-3. Molecular formula: C20H19N5O3. Mole weight: 377.4. | |
| GSK2982772 | GSK2982772 is a potent, orally active and ATP competitive RIP1 kinase inhibitor with IC50 values of 16 nM and 20 nM for human and monkey RIP1, respectively[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1622848-92-3. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101760. | |
| GSK2982772 | GSK2982772 is a potent and selective receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate for the Treatment of Inflammatory Diseases. GSK2982772 is, currently in phase 2a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis. GSK2982772 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. RIP1 has emerged as an important upstream kinase that has been shown to regulate inflammation through both scaffolding and kinase specific functions. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK2982772; GSK-2982772; GSK 2982772. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1622848-92-3. Molecular formula: C20H19N5O3. Mole weight: 377.4. Purity: >98%. IUPACName: (S)-5-Benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b]-[1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide. Canonical SMILES: O=C(C1=NN=C(CC2=CC=CC=C2)N1)N[C@@H]3C(N(C)C4=CC=CC=C4OC3)=O. Product ID: ACM1622848923. Alfa Chemistry ISO 9001:2015 Certified. | |
| GSK2983559 | GSK2983559 is a potent, selective and oral active inhibitor of receptor interacting protein 2 (RIP2) kinase. GSK2983559 exhibits activity in blocking many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples. Synonyms: RIP2 kinase inhibitor 1; RIPK2-IN-1; GSK-2983559; GSK 2983559. CAS No. 1579965-12-0. Molecular formula: C21H23N4O7PS2. Mole weight: 538.53. | |
| GSK2983559 | GSK2983559 is an orally active and potent receptor interacting protein 2 (RIP2) kinase inhibitor. GSK2983559 blocks many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples[1]. Uses: Scientific research. Group: Signaling pathways. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112038A. | |
| GSK2983559 active metabolite | GSK2983559 active metabolite is an active metabolite of GSK2983559. GSK2983559 active metabolite is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1. Uses: Scientific research. Group: Signaling pathways. CAS No. 1423186-80-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19764. | |
| GSK299115A | GSK299115A is a G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor. Synonyms: GSK299115A; GSK 299115A; GSK-299115A. 4-(3,4-dichlorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyridine-5-carboxamide. Grade: 98%. CAS No. 864082-35-9. Molecular formula: C20H16Cl2N4O2. Mole weight: 415.27. | |
| GSK299423 | GSK299423 is an antibiotic agent and it seems potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. GSK299423 is a Type II bacterial DNA topoisomerase inhibitor under the development of GlaxoSmithKline. Early research for the treatment of Gram-negative infections and Nosocomial infections was on-going in USA. Uses: Gram-negative infections; nosocomial infections. Synonyms: GSK299423; GSK 299423; GSK-299423; 4-(2-(4-(([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino)piperidin-1-yl)ethyl)-6-methoxyquinoline-3-carbonitrile. Grade: 98%. CAS No. 1352149-24-6. Molecular formula: C25H27N5O2S. Mole weight: 461.58. | |
| GSK3004774 | GSK3004774 is a potent, nonabsorbable, gastrointestinally-restricted CaSR agonist, with an EC50 of 50 nM for human and pEC50s of 7.3, 6.6 and 6.5 for human, mouse and rat, respectively. Synonyms: 1-[3-({4-[(3R)-3-{[(1S)-1-(1-Naphthyl)ethyl]amino}-1-pyrrolidinyl]benzoyl}amino)propyl]-4-piperidinecarboxylic acid; 4-Piperidinecarboxylic acid, 1-[3-[[4-[(3R)-3-[[(1S)-1-(1-naphthalenyl)ethyl]amino]-1-pyrrolidinyl]benzoyl]amino]propyl]-. Grade: ≥97%. CAS No. 2138814-32-9. Molecular formula: C32H40N4O3. Mole weight: 528.69. | |
| GSK3004774 | GSK3004774 is a potent, nonabsorbable agonist of CaSR , with an pEC 50 of 7.3, 6.6 and 6.5 for human, mouse and rat CaSR, respectively. GSK3004774 shows an EC 50 of 50 nM for human CaSR [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2138814-32-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-107773. | |
| GSK 3008348 | GSK 3008348 is a small molecule integrin αvβ6 antagonist, extracted from patent WO/2014154725A1, example 1. The affinity (pIC50) for the human - a 6 protein in the Fluorescence Polarisation Assay for Integrin Antagonist 1 was 8.1, whereas its affinity in the cell Adhesion Assays was for: ανβ6 (pIC50 = 8.4); ανβ3 (pIC50 = 6); ανβ5 (pIC50 = 6.9); ανβ8 (pIC50 = 7.7). Uses: Scientific research. Group: Signaling pathways. CAS No. 1629249-33-7. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19767. | |
| GSK-3008348 | GSK-3008348 is an integrin αvβ6 antagonist developed for the treatment of idiopathic pulmonary fibrosis (IPF). Synonyms: GSK 3008348; GSK3008348. Grade: 98% by HPLC. CAS No. 1629249-33-7. Molecular formula: C29H38ClN5O2. Mole weight: 524.1. | |
| GSK 3008348 hydrochloride | GSK 3008348 hydrochloride is a small molecule integrin αvβ6 antagonist, extracted from patent WO/2014154725A1, example 1. The affinity (pIC50) for the human - a 6 protein in the Fluorescence Polarisation Assay for GSK 3008348 (hydrochloride) is 8.1, whereas its affinity in the cell Adhesion Assays was for: ανβ6 (pIC50 = 8.4); ανβ3 (pIC50 = 6); ανβ5 (pIC50 = 6.9); ανβ8 (pIC50 = 7.7). Uses: Scientific research. Group: Signaling pathways. CAS No. 1629249-40-6. Pack Sizes: 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-19767A. | |
| GSK3117391 | GSK3117391, a HDAC inhibitor, was developed by GSK considering its potential effect in the treatment of arthritis and rheumatoid. It was already being terminated the phase 1 trial. Uses: Gsk3117391, a hdac inhibitor, was developed by gsk considering its potential effect in the treatment of arthritis and rheumatoid. Synonyms: GSK3117391; GSK-3117391; GSK 3117391; GSK3117391A; GSK-3117391A; GSK 3117391A; HDAC-IN-3; SCHEMBL15144242; AFDPFLDWOXXHQM-NRFANRHFSA-N; CS-5448; HY-19772; 121555-EP2295410A1. Grade: 95%. CAS No. 1018673-42-1. Molecular formula: C22H33N3O4. Mole weight: 403.52. | |
| GSK3117391 | GSK3117391 (ESM-HDAC391) is a histone deacetylase (HDAC) inhibitor, extracted from patent WO/2008040934 A1. Uses: Scientific research. Group: Signaling pathways. Alternative Names: ESM-HDAC391; CHR-5154; HDAC-IN-3. CAS No. 1018673-42-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19772. | |
| GSK3145095 | GSK3145095 is an orally active RIP1 kinase inhibitor with IC50 of 6.3 nM. It potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking RIP1 kinase-dependent cellular responses. Synonyms: GSK 3145095; GSK-3145095. CAS No. 1622849-43-7. Molecular formula: C20H17F2N5O2. Mole weight: 397.38. | |
| GSK3145095 | GSK3145095 is a RIP1 kinase inhibitor with an IC 50 of 6.3 nM [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1622849-43-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111946. | |
| GSK317354A | GSK317354A is a G-Protein-Coupled Receptor Kinase 2 (GRK2) inhibitor,but no detailed information has been published yet. Synonyms: GSK317354A; GSK-317354A; GSK 317354A. 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1,4-dihydropyrimidine-5-carboxamide. Grade: 98%. CAS No. 874119-13-8. Molecular formula: C25H18F4N6O. Mole weight: 494.45. | |
| GSK3179106 | GSK3179106 is an orally active and selective RET kinase inhibitor with IC50s of 0.4 nM, 0.2 nM for human RET and rat RET, respectively. GSK3179106 has the potential for irritable bowel syndrome (IBS) through the attenuation of post-inflammatory and stress-induced visceral hypersensitivity[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1627856-64-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-100459. | |
| GSK321 | GSK321 is a highly potent, selective inhibitor of mutant IDH1 enzymes, with IC50=4.6 nM against R132H, 3.8 nM against R132C and 2.9 nM against R132G. GSK321 stably decreased 2-hydroxyglutarate (2-HG) production in several different IDH1 mutant AML cells within a 2-3 week time frame ex vivo. Because of the allosteric nature of the interaction, GSK321 is able to inhibit multiple mutant forms of IDH1, which is consistent with our cell biological observations. Furthermore, GSK321 retains excellent potency in cells, since it does not compete with the tightly bound cofactor. Synonyms: (7R)-1-[(4-fluorophenyl)methyl]-N-[3-[(1S)-1-hydroxyethyl]phenyl]-7-methyl-5-(1H-pyrrole-2-carbonyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-3-carboxamide; (7R)-1-[(4-fluorophenyl)methyl]-N-[3-[(1S)-1-hydroxyethyl]phenyl]-7-methyl-5-(1H-pyrrole-2-carbonyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-3-carboxamide; GSK321; GSK 321; GSK-321; BDBM195601. Grade: >98%. CAS No. 1816331-63-1. Molecular formula: C28H28FN5O3. Mole weight: 501.56. | |
| GSK329 | GSK329 is a potent and selective inhibitor of cardiac-specific kinase TNNI3K (TNNI3 interacting kinase) with IC50 of 10 nM. Synonyms: GSK-329; GSK 329; N-(3,5-dichloro-4-{[6-(methylamino)pyrimidin-4-yl]oxy}phenyl)-N'-[3-(trifluoromethyl)phenyl]urea; N-[3,5-Dichloro-4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]-N-[3-(trifluoromethyl)phenyl]-urea. Grade: 98% by HPLC. CAS No. 1268490-12-5. Molecular formula: C19H14Cl2F3N5O2. Mole weight: 472.2. | |
| GSK329 | GSK329 is a highly potent and moderately selective TNNI3K inhibitor. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK329; GSK-329; GSK 329. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1268490-12-5. Molecular formula: C19H14Cl2F3N5O2. Mole weight: 472.24. Purity: >98%. IUPACName: N-[3,5-Dichloro-4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]-N-[3-(trifluoromethyl)phenyl]-urea. Canonical SMILES: O=C(N)N(C1=CC(Cl)=C(OC2=NC=NC(NC)=C2)C(Cl)=C1)C3=CC=CC(C(F)(F)F)=C3. Product ID: ACM1268490125. Alfa Chemistry ISO 9001:2015 Certified. Categories: GSK 299423. | |
| GSK3326595 | GSK3326595 is a protein arginine methyltransferase 5 ( PRMT5 ) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma [1] [2] [3] [4] [5]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: EPZ015938. CAS No. 1616392-22-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-101563. | |
| GSK3326595 | GSK3326595, also called as EPZ015938, is an orally available and specific inhibitor of protein arginine methyltransferase 5 (PRMT5) that potently inhibits tumor growth in vitro and in vivo in animal models and has entered clinical trials for the treatment of solid tumors and non-Hodgkin's lymphoma. Synonyms: GSK-3326595; GSK 3326595; GSK3326595; EPZ015938; EPZ 015938; EPZ-015938; 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]pyrimidine-4-carboxamide. CAS No. 1616392-22-3. Molecular formula: C24H32N6O3. Mole weight: 452.55. | |
| GSK334429 hydrochloride | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK3368715 3HCl | GSK3368715 is a potent reversible inhibitor of type I protein arginine methyltransferases (PRMT) with antitumor activity. Synonyms: EPZ019997 3HCl. CAS No. 2227587-26-8. Molecular formula: C20H41Cl3N4O2. Mole weight: 475.92. | |
Our database is helping our users find suppliers everyday.
